• Chronic Obstructive Pulmonary Disease (COPD) has a high burden to society*: ->800,000 are diagnosed with COPD -$3,196 CAD$ (2003) total annual costs/patient -4 th and 6 th leading cause of death in men and women, respectively
• Several classes of medications for COPD (short and long-acting anticholinergics, short-and long-acting beta-agonists, oral or inhaled corticosteroids, theophylline)
• Little is known about combination therapy. Optimal RCT cont.
• # of patients: TP=156, TS=148, TFS=145
• Primary outcome: Proportion of exacerbation-free patients at the end of one-year follow-up: Methods cont.
• Rigorous sensitivity analysis: nested imputation and bootstrap
• Two sources of uncertainty: incomplete follow-up and finite sample size of the study Methods cont.
Mortalities
• 14 died during the trial TP=3, TS=6, TSF=5
• By definition, all costs and utilities after death were set to zero.
• For the exacerbation outcome-
•Setting zero effectiveness after death is problematic as the treatment arm had excess mortality.
• For exacerbations, death was treated as attrition (forced dropout)
• Sensitivity analysis Results (outcomes)
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